David J. Harrison, PhD

For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.

Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.

This study applied a validated algorithm to estimate the effectiveness and costs of the index biologic used by 4696 US veterans with rheumatoid arthritis.

Among rheumatoid arthritis patients newly treated with adalimumab, etanercept, or infliximab, lower dose escalation rates and costs were seen with etanercept.